MNKD — MANNKIND CORP

—
Nasdaq · Health Care · Pharmaceuticals · CIK 899460 ·
Last close
$4.07
Market Cap
$1.31B
52W High
$6.51
52W Low
$2.23
ADV30
3,648,405
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 101,870,000 78,358,000 -2,574,000 -23,224,000 722,616,000 41,276,000 759,882,000
Jun 2026 109,375,000 79,835,000 -835,000 -19,032,000 732,304,000 52,929,000 799,501,000
Mar 2026 90,171,000 72,698,000 -2,985,000 -16,619,000 744,403,000 52,834,000 803,598,000
Dec 2025 111,955,000 82,282,000 -7,690,000 -15,948,000 792,182,000 74,882,000 843,204,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,054,000
Investing CF
$-280,387,000
Financing CF
$284,372,000
CapEx
$-10,081,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-3,231,607,000
Inventory
$44,419,000
Receivables
$43,207,000
ST Investments
$58,201,000
EBIT TTM
$-506,000
Pretax Income TTM
$-48,654,000
Interest Exp TTM
$48,148,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$413,371,008
EBITDA
$-1,942,000
Free Cash Flow
$-19,861,250
Enterprise Value
$1,735,910,400
Total Cash
$96,609,000
Total Debt
$578,123,008
Shares Out
321,640,118
Trailing EPS
$-0.24
Book Value
$-0.12
ROE
—
ROA
-1.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 348,966,000 46,550,000 5,863,000 792,182,000 843,204,000 -51,022,000 18,255,000
Dec 2024 285,504,000 68,680,000 27,588,000 393,843,000 472,659,000 -78,816,000 42,511,000
Dec 2023 198,962,000 10,594,000 -11,938,000 475,198,000 721,366,000 -246,168,000 34,094,000
Dec 2022 99,770,000 -68,921,000 -87,400,000 295,282,000 545,820,000 -250,538,000 -80,679,000

TTM Snapshot

Revenues TTM
$393,630,000
NetIncome TTM
$-43,614,000
OpCashFlow TTM
—
Assets (Latest)
$732,304,000
Forward EPS
$0.14

Peers — same industry

TickerNameMarket CapLastDaily %
LBRX LB PHARMACEUTICALS INC $1.30B $40.30 —
GPCR Structure Therapeutics Inc. $1.30B $18.17 —
INVA Innoviva, Inc. $1.30B $18.30 —
OCUL OCULAR THERAPEUTIX, INC $1.32B $6.02 —
MLYS Mineralys Therapeutics, Inc. $1.28B $14.48 —

News headlines (Yahoo Finance, 1h cache)

MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction
2026-11-18 12:13 · Yahoo
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
2026-11-18 05:12 · Yahoo
MannKind to Participate in Upcoming Investor Conferences
2026-11-10 13:00 · Yahoo
MannKind (MNKD) Q3 2026 Earnings Call Transcript
2026-11-06 14:44 · Yahoo
MannKind Corporation Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
MannKind Corp (MNKD) Q3 2026 Earnings Call Highlights: Revenue Jumps 24% as FuroSix ReadyFlow ...
2026-11-06 11:19 · Yahoo
Is MannKind (MNKD) Trading At A Discount Following Its Mixed Third Quarter Results?
2026-11-06 10:13 · Yahoo
MannKind Q3 Earnings Call Highlights
2026-11-06 07:14 · Yahoo
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
2026-11-05 22:30 · Yahoo
MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 21:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.